Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69,362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.
Liu SY, Dong S, Yang XN, Liao RQ, Jiang BY, Wang Q, Ben XS, Qiao GB, Lin JT, Yan HH, Yan LX, Nie Q, Tu HY, Wang BC, Yang JJ, Zhou Q, Li HR, Liu K, Wu W, Liu SM, Zhong WZ, Wu YL. Liu SY, et al. Among authors: wang bc, wang q. Signal Transduct Target Ther. 2023 Dec 6;8(1):442. doi: 10.1038/s41392-023-01700-4. Signal Transduct Target Ther. 2023. PMID: 38057314 Free PMC article. Clinical Trial.
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.
Wu YL, Wang CL, Sun Y, Liao ML, Guan ZZ, Yang ZM, Zhou QH, Lu S, Cheng Y, Liu XQ, Zhang XC, Zhou C, Wang J, Zhou Q, Song Y, Han BH, Ma ZY, Yang F, Wang Q, Chuai SK, Shao Y, He W, Zhu G, Xiong L, Wang JJ, Chen KN, Zhang L, Mao WM, Ma SL, Feng JF, Yang XN, Xu L, Chen G, Zhao J, Song QB, Shen-Tu Y, Qiao GB, Yu D, Yu SY, Hu Y, Chen M, Chen GY, Fan Y, Zhang HL, Liang J, Zhu GY, Cui JW, Yang JJ, Zhao Q, Zhao MF, Lu Y, Chang JH, Li JL, Yang Y, Hu J, Gu CD, Zhang YC, Zhong WZ. Wu YL, et al. Among authors: wang jj, wang j, wang cl, wang q. ESMO Open. 2017 Apr 4;2(Suppl 1):e000174. doi: 10.1136/esmoopen-2017-000174. eCollection 2017. ESMO Open. 2017. PMID: 28848676 Free PMC article. Review.
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Among authors: wang j, wang bh, wang q. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.
Wu YL, Wang CL, Liao ML, Guan ZZ, Gao CY, Lu S, Zhao MF, Wang J, Liu XQ, Yang JJ, Liang J, Mao WM, Han BH, Zhang XC, Song Y, Feng JF, Ma SL, Wu G, Zhou CC, Chen KN, Cheng Y, He Y, Chen C, Wang Q, Lin JZ, Zhu B, Liu YP, Hu Y, Qiao GB, Zhou Q, Song QB, Wu N, Wu L, Huang C, Fu XL, Xiong JP, Hu J, Hu CP, Chang JH, Zhao Q, Zhao J, Zhou PH, Ma ZY, Chen Y, Zhang HL, Yang F, Wang JJ, Pan YY, Yang XN, Fan Y, Liu Z, Fan W, Yang N, Guan YF, Sun H, Zhong WZ. Wu YL, et al. Among authors: wang jj, wang j, wang cl, wang q. Transl Lung Cancer Res. 2018 Jun;7(3):428-436. doi: 10.21037/tlcr.2018.04.15. Transl Lung Cancer Res. 2018. PMID: 30050780 Free PMC article. Review.
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104).
Xu ST, Xi JJ, Zhong WZ, Mao WM, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhang YX, Yin JC, Wang Q, Wu YL. Xu ST, et al. Among authors: wang j, wang bh, wang q. J Thorac Oncol. 2019 Mar;14(3):503-512. doi: 10.1016/j.jtho.2018.11.020. Epub 2018 Dec 3. J Thorac Oncol. 2019. PMID: 30521970 Free article. Clinical Trial.
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, Xu L, Wang CL, Chen MW, Kang X, Yan W, Yan HH, Liao RQ, Yang JJ, Zhang XC, Zhou Q, Wu YL. Zhong WZ, et al. Among authors: wang j, wang q, wang cl. J Clin Oncol. 2019 Sep 1;37(25):2235-2245. doi: 10.1200/JCO.19.00075. Epub 2019 Jun 13. J Clin Oncol. 2019. PMID: 31194613 Clinical Trial.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
Zeng J, Mao WM, Chen QX, Luo TB, Wu YL, Zhou Q, Yang XN, Yan HH, Zhong WZ, Wang Q, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT. Zeng J, et al. Among authors: wang j, wang bh, wang q. Lung Cancer. 2020 Dec;150:164-171. doi: 10.1016/j.lungcan.2020.09.027. Epub 2020 Oct 8. Lung Cancer. 2020. PMID: 33186858 Clinical Trial.
69,362 results
You have reached the last available page of results. Please see the User Guide for more information.